STOCK TITAN
  1. Home
  2. Sec-filings
  3. BLFS
  4. [Form 4] BIOLIFE SOLUTIONS INC Insider Trading Activity

BLFS insider filing: Joydeep Goswami sells 1,666 shares, holds 44,986

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

BioLife Solutions (BLFS) reported an insider transaction on Form 4. Director Joydeep Goswami sold 1,666 shares of Common Stock on 10/24/2025 at a price of $28.99 per share, coded as an open-market sale (S). The transaction was executed under a Rule 10b5-1(c) trading plan effective 12/13/2024. Following this sale, Goswami beneficially owns 44,986 shares, held directly.

Positive

  • None.

Negative

  • None.
Insider GOSWAMI JOYDEEP
Role Director
Sold 1,666 shs ($48K)
Type Security Shares Price Value
Sale Common Stock 1,666 $28.99 $48K
Holdings After Transaction: Common Stock — 44,986 shares (Direct)
Footnotes (1)
  1. [object Object]
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
GOSWAMI JOYDEEP
(Last) (First) (Middle)
3303 MONTE VILLA PARKWAY
SUITE 310
(Street)
BOTHELL WA 98021
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
BIOLIFE SOLUTIONS INC [ BLFS ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
10/24/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/24/2025 S(1) 1,666 D $28.99 44,986 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The sales reported were effected pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 12-13-2024.
Remarks:
/s/ Joydeep Goswami 10/28/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did BLFS disclose in this Form 4?

A Director, Joydeep Goswami, sold 1,666 shares of BioLife Solutions common stock at $28.99 on 10/24/2025.

Who is the insider involved in the BLFS transaction?

The reporting person is Joydeep Goswami, a Director of BioLife Solutions.

How many BLFS shares does the insider hold after the sale?

Following the transaction, he beneficially owns 44,986 shares, held directly.

Was the BLFS sale under a Rule 10b5-1 plan?

Yes. The sale was made under a Rule 10b5-1(c) trading plan effective 12/13/2024.

What was the transaction code for the BLFS trade?

The filing lists transaction code S, indicating an open-market sale.

What was the price per BLFS share sold?

The reported sale price was $28.99 per share.